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PI16 is a shear stress and 
inflammation-regulated  
inhibitor of MMP2
Georgina G. J. Hazell1, Alasdair M. G. Peachey1, Jack E. Teasdale1, Graciela B. Sala-Newby1, 
Gianni D. Angelini1, Andrew C. Newby1 & Stephen J. White1,2
Raised endothelial shear stress is protective against atherosclerosis but such protection may be lost 
at sites of inflammation. We found that four splice variants of the peptidase inhibitor 16 (PI16) mRNA 
are among the most highly shear stress regulated transcripts in human coronary artery endothelial 
cells (HCAECs), in vitro but that expression is reduced by inflammatory mediators TNFα and IL-1β. 
Immunohistochemistry demonstrated that PI16 is expressed in human coronary endothelium and in a 
subset of neointimal cells and medial smooth muscle cells. Adenovirus-mediated PI16 overexpression 
inhibits HCAEC migration and secreted matrix metalloproteinase (MMP) activity. Moreover, PI16 
inhibits MMP2 in part by binding an exposed peptide loop above the active site. Our results imply that, 
at high endothelial shear stress, PI16 contributes to inhibition of protease activity; protection that can 
be reversed during inflammation.
Endothelial cells (ECs) are mechanosensitive, their behaviour being profoundly affected by both cyclic strain and 
the frictional force (shear stress) exerted by the blood flowing over their surface. ECs are exposed to a range of 
different shear stress environments in vivo, reviewed1–3. Disturbed/reversing flow, which produces low average 
and oscillatory shear stress (OSS), promotes an ‘activated and inflammatory’ EC phenotype that is proathero-
genic: it also reduces antioxidant production, increases reactive oxygen species (ROS) production, encourages 
vascular leakage (by increasing the permeability of the endothelial cell barrier) and favours coagulation and thom-
bosis. By contrast, normal laminar shear stress (LSS) (10–15 dynes/cm2 in the coronary circulation)4–7 induces 
EC quiescence, resistance to inflammation (by inducing a myriad of anti-inflammatory genes and repressing 
pro-inflammatory gene expression) and stimulates the release of anti-coagulative and anti-thombolytic mediators, 
all of which are atheroprotective8–10. In advanced atherosclerosis, ECs overlying stenotic atherosclerotic plaques 
are exposed to elevated shear stress (ESS), potentially exceeding 300 dynes/cm2 5,7,11–14. However, the effects of ESS 
on ECs is less well studied. We previously reported that acute exposure to ESS (75 dynes for 24 h) modifies pri-
mary human umbilical vein EC behaviour compared to normal LSS, for example, altering MAP kinase signalling 
and reducing ROS levels and intracellular cAMP concentrations15. Similarly, Dolan and colleagues showed that 
exposing cultured bovine ECs to ESS of 10 Pa (100 dynes/cm2) for 24 h promotes the proliferation and pro-matrix 
remodelling behaviour, as well up-regulating the expression of anti-coagulant and anti-inflammatory genes16. 
Furthermore, the ECs overlying stenotic atherosclerotic plaques express markers of inflammation17,18, despite 
their exposure to ESS. The interaction of ESS and inflammation is therefore of particular pathological significance.
As we recently reviewed19, excessive extracellular proteolysis may also be a key factor underlying the loss of ECs 
during surface erosion from plaques, a phenomenon that can precipitate life-threatening myocardial infarctions. 
Extracellular proteases are also important regulators of EC attachment, migration and invasion, during angiogenesis20. 
Proteases are also essential in adaptive, EC-regulated arterial remodelling in response to flow21,22. For these reasons, 
our present study focussed on PI16 (also known as peptidase inhibitor 16, PSPBP, or CRISP-1), which is a member 
of the cysteine-rich secretory proteins, antigen 5, and pathogenesis-related 1 proteins (CAP) superfamily, and has 
homologues in other mammalian species including rat and mouse (reviewed in ref. 23). We found that PI16 is highly 
up-regulated by LSS and ESS in primary human coronary artery endothelial cells (HCAECs). However, PI16 is pro-
foundly downregulated by pro-inflammatory cytokines. Using phage display we identified matrix metalloproteinase-2 
(MMP-2) as a target for PI16 inhibition. Furthermore, we showed that PI16 inhibits EC migration.
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Results
Laminar shear stress increased PI16 expression. Normal laminar shear stress (15 dynes/cm2 - LSS) 
and elevated laminar shear stress (75 dynes/cm2 – ESS) significantly increased the expression of PI16 tran-
script and protein in HCAECs compared with oscillatory shear stress (+ /− 5 dynes/cm2 – OSS) (Fig. 1A,B). LSS 
induced a 119-fold increase in mRNA (P < 0.001; Fig. 1A) and 7-fold increase in protein (P < 0.01; Fig. 1B). The 
expression was further elevated between LSS and ESS with a 9-fold increase in mRNA (P < 0.001; Fig. 1A) and 
a 5-fold increase in protein (P < 0.001; Fig. 1B). Results were confirmed with immunocytochemical staining of 
HCAEC exposed to shear stress, with a higher relative level of positive PI16 immunoreactivity in cells exposed to 
ESS when compared to LSS or OSS (Fig. 1C).
Four alternatively spliced PI16 mRNA variants have been previously identified, three that give rise to the full 
length 463aa PI16 protein (Supplementary Fig. 1, hereafter denoted as PI16 protein isoform 1) and a shorter 
270aa isoform (isoform 2). Whilst cloning the PI16 gene for adenoviral construction, we identified a further 
two previously undescribed isoforms that are expressed by HCAECs, (hereafter referred to as PI16 protein 
isoforms 3 and 4) which translate into two distinct proteins (260aa and 225aa polypeptides respectively, see 
Supplementary Fig. 2). RT-qPCR analysis revealed that all of the isoforms were up-regulated in the same way by 
shear stress (Supplementary Fig. 3A).
PI16 is expressed in HCAECs in vivo. Using histological sections of human coronary arteries from 
cadaveric donors, PI16 was clearly detected in luminal ECs (stained with UEA lectin) (Fig. 1D). Some of the cells 
in the intimal and medial smooth muscle cells were also positive for PI16 (Supplementary Fig. 4). IgG control 
sections were devoid of immunoreactivity.
ERK5 signalling mediates upregulation of PI16 expression by elevated shear stress. 
Mitogen-activated protein kinase 7 (MAPK7), also known as Extracellular-Signal-Regulated Kinase 5 (ERK5), is 
strongly activated in response to shear stress. Moreover, the ERK5 signalling pathway has been shown to mediate 
some of the effects of LSS on ECs24–26. We therefore investigated whether ERK5 mediates PI16 upregulation in 
response to ESS. When HCAECs were exposed to ESS for 24 h in the presence of an ERK5 inhibitor, BIX02189 
(ERK5i; 10 μ M), the expression of PI16 mRNA (Fig. 2A; 8-fold reduction; P < 0.05) and protein expression 
(Fig. 2B; 4-fold reduction; P < 0.05) were significantly reduced in comparison to vehicle controls. This suggests 
that the shear-induced increase in PI16 expression is mediated by an ERK5-dependant pathway.
Acute and chronic inflammation greatly reduces PI16 expression. We also investigated whether 
PI16 expression is regulated by atheroma-related pro-inflammatory cytokines, TNFα or IL-1α . Exposure of 
HCAECs to TNFα or IL-1α significantly reduced both the level of PI16 mRNA at ESS (Fig. 2C; TNFα , 5-fold 
reduction, P < 0.01; IL-1α , 2-fold reduction, P < 0.01) and protein expression (Fig. 2D; TNFα , 13.5-fold decrease, 
P < 0.05; IL-1α , 3-fold decrease, P < 0.05), when compared with vehicle controls. A similar reduction in PI16 
mRNA and protein expression was observed at ESS for 72 h, with TNFα added for the last 48 h (to allow the cells 
24 hours to adapt to their shear environment before treatment) (Fig. 2E,F).
PI16 inhibits migration of HCAECs. Extracellular proteases are known to participate in cell motility20,27. 
Consequently, we hypothesised that adenoviral overexpression of PI16 would inhibit cell migration. Adenoviral 
overexpression of PI16 significantly reduced the migration of HCAECs into a ‘scratch wound’ in vitro when 
compared to β -gal transduced adenoviral control (40% reduction, P < 0.05; Fig. 3A). There was no difference 
in migration between β -gal adenoviral control and uninfected controls (Fig. 3A). Overexpression of β -gal or 
PI16 did not have any significant effect on the proliferation rates of HCAECs in confluent regions away from the 
scratch wound but PI16 overexpression significantly reduced proliferation in the migration zone (Fig. 3B). Cells 
were stained for PI16 to confirm transfection efficiency (Fig. 3E). PI16 immunoreactivity was detected in cultures 
infected with PI16 adenovirus but was absent in β -gal virus infected control cultures, as these experiments were 
performed under static culture conditions (Fig. 3E).
PI16 overexpression reduces MMP activity in HCAECs. It is known that matrix metalloproteinases 
(MMPs) are essential for endothelial migration20. Hence, we examined whether adenovirus driven PI16 produc-
tion has the ability to inhibit MMP activity in cultures of HCAECs treated with TNFα to upregulate endogenous 
MMP release. Consistent with our hypothesis, there was a significant reduction of MMP activity in conditioned 
media from AdPI16 compared to Adβ -gal transduced HCAECs (Fig. 4A).
Identification of MMP2 as a PI16 binding-partner using phage display. Phage display was used to 
identify peptides with high affinity for PI16, which might mediate binding and protease inhibition. Phage were 
isolated by cell surface bio-panning28,29 using HeLa cells (as they express low levels of PI16, by western blotting 
– not shown) infected with adenoviruses to overexpress PI16 or β -gal. Of particular interest, we isolated a pep-
tide containing the sequence TGPRSDGF that had high homology with amino acids 250–256 (TG-RSDGF) of 
matrix metalloproteinase 2 (MMP2). These residues form an exposed loop adjacent to the active site, suggesting 
that PI16 may be an MMP2 inhibitor (Fig. 4B). Confirming this, recombinant PI16 produced in E. coli showed a 
strong inhibition of recombinant MMP2 activity (IC50 ~10 nM, Fig. 4C). Moreover, the phage-display-derived 
peptide TGPRSDGF or the corresponding sequence on MMP2, TG-RSDGF (lacks proline), reversed the inhibi-
tion of MMP2 activity by PI16, demonstrating that this peptide loop contributed to the binding of PI16 to MMP2.
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Discussion
Normal laminar shear stress initiates a phenotypic shift in ECs, promoting a more-quiescent, less-permeable, 
anti-inflammatory and athero-protective state. This study demonstrates that shear upregulates PI16 in HCAECs 
through activation of ERK5-dependent pathways. Moreover, PI16 inhibits endothelial migration and related pro-
liferation, helping to maintain quiescence at high shear. PI16 up-regulation is reversed by inflammatory media-
tors, suggesting that this protective effect is lost in inflamed endothelium. Most importantly, MMP2 is identified 
for the first time as a target for PI16 inhibition.
We found that exposure to LSS for 72 h increased PI16 mRNA expression over 100-fold, compared to OSS. 
The magnitude of up-regulation was similar for all four splice variants that we identified in HCAECs, suggesting 
that shear regulates PI16 expression predominantly at the level of transcription. Protein expression mirrored the 
increases in mRNA level. Inhibition of PI16 mRNA and protein expression with the ERK5 inhibitor, BIX02189, 
suggests that ERK5 mediates shear upregulation of PI16, similarly to many other shear-regulated genes24–26. 
Figure 1. PI16 expression is increased by shear stress in HCAEC and is expressed in human coronary 
arteries. Reulation of mRNA (A) and protein (B) expression in HCAEC flowed for 72 h (n = 6; **P < 0.01, 
***P < 0.001 compared to OSS control). (C) ICC staining corroborates western analysis, with highest PI16 
expression (green) in cells exposed to ESS (blue DAPI stain highlights cell nuclei). (D) IHC analysis revealed 
PI16 staining (green) in ECs (endothelial cell marker, UEA in red). DAPI staining was used to demarcate the 
nuclei (blue).
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Figure 2. PI16 expression is regulated by ERK5 and modulated by inflammatory cytokines. To investigate 
whether ERK5 modulates PI16 expression, ESS was applied to HCAECs for 24 h in the presence of an ERK5 
inhibitor BIX02189 (ERK5i; 10 μ M). There was a significant reduction in PI16 mRNA (A) and protein (B) 
expression in HCAECs exposed to laminar shear when compared to the vehicle control (n = 3; *P < 0.05 
compared to vehicle control, **P < 0.01 compared to untreated control). We also investigated the regulation of 
PI16 expression in the presence of inflammatory cytokines, TNFα and IL-1α , which significantly reduced PI16 
mRNA (C) and protein (D) expression in HCAECs exposed to ESS for 24 h when compared with the vehicle 
controls (n = 3; *P < 0.05, **P < 0.01, ***P < 0.001). To exclude the possibility that cytokine treatment affected 
the adaptation of HCAECs to ESS, a further ‘chronic’ experiment was performed, HCAEC were exposed to ESS 
for 24 h prior to the first dose of TNFα . 3 doses of TNFα were added to the flow systems at 16 h intervals. TNFα 
treatment significantly reduced PI16 mRNA (E) and protein (F) expression (n = 3; *P < 0.05, ***P < 0.001) 
compared to vehicle controls.
www.nature.com/scientificreports/
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Figure 3. Effect of PI16 on migration and proliferation of HCAECs. Adenoviral-overexpression of PI16 
significantly reduced the movement of HCAECs in a migration assay when compared to the β -gal adenoviral-
controls (*P < 0.05 compared to β -gal control, **P < 0.01 compared to untreated control; n = 5) ((A) and 
representative image (B)). Staining for PI16 (red) revealed that the PI16-viral vector achieved ~100% cell 
transduction. Cells were also stained for BrdU to measure cell proliferation (brown). PI16 overexpression 
significantly reduced proliferation in the migration zone (C), ***P < 0.01 compared to controls), however did 
not affect the proliferation rate in non-migrating cells (D). (E) Representative images, BrdU staining in brown, 
PI16 staining in red.
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This observation would be strengthened by gene knock-down experiments. Furthermore, transcription factor 
Kruppel-like factor 2 (KLF2) is known to mediate many of the protective effects of shear that are downstream of 
ERK530. Examination of supplementary gene array data from a study by Parmer et al.26 revealed that atheropro-
tective shear stress induced a 25-fold increase in PI16 expression in HUVECs compared to static controls, adding 
weight to our observations in HCAECs. This effect was reversed in the transcriptome after knock-down of KLF2, 
whereas the transcriptome observed after adenoviral overexpression of KLF2 showed a 64-fold increase in PI16 
expression in HUVECs26. Although none of these findings were discussed by Parmer et al., they provide a con-
vincing explanation for the shear regulation of PI16 expression.
Figure 4. PI16 reduces MMP activity. (A) Concentrated conditioned media from control or PI16 over-
expressing HCEACs was assessed for MMP activity using a quenched-fluorogenic substrate OmniMMP. In 
comparison to all controls, PI16 conditioned media showed the lowest MMP activity (*p < 0.05, n = 5). (B) 
Phage display identified a peptide containing the sequence TGPRSDGF, with high homology to amino acids 
250–256 of MMP2 TG-RSDGF, corresponding to a peptide loop situated above the active site of MMP2. (C) 
Recombinant MMP2 (5.5 nM) was incubated with increasing concentrations of PI16 for 30 minutes before 
the addition of OmniMMP. Relative fluorescence 30 minutes after addition of OmniMMP is presented. Graph 
combines data from 3 separate preparations of recombinant PI16. Concentrations above 10 nM resulted in a 
significant reduction of MMP2 activity (P < 0.05, n = 3–23). (D) Inclusion of peptides TGRSDGF (pep) or 
TGPRSDGF (pep + P) (10 μ M), with 10 nM PI16 reduced the inhibition of MMP2 (*p < 0.05 compared to all 
other conditions, n = 3).
www.nature.com/scientificreports/
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Conversely, PI16 expression was strongly suppressed by inflammatory mediators, IL-1β and TNFα that act 
through the NF-κ B signalling pathway. The mutual antagonism of pathways mediated by KLF2 and NF-κ B has 
been extensively described previously1,30–32. Our studies extend this concept to expression of PI16.
It is possible to speculate on the relevance of these findings to human disease, particularly to endothelial 
erosion, a process responsible for ~30% of myocardial infarctions33. The upregulation of PI16 by KLF2 would 
suggest it plays an athero-protective role in the endothelium, by limiting proteolysis of the sub-endothelial matrix. 
This would help resist the increased mechanical forces to which the endothelium is exposed, especially overlying 
stenotic plaques, where the level of shear stress can exceed 300 dynes/cm2 5,7,11–14. Cigarette use is a risk factor for 
endothelial erosion33 and is known to increase the circulating levels of inflammatory cytokines, including TNFα 34. 
Downregulation of PI16 by circulating and plaque-derived inflammatory cytokines may therefore reduce protec-
tion from proteolysis and render the sub-endothelial matrix more susceptible to degradation and the endothe-
lium to detachment.
Structural analysis of the full length PI16 protein suggests that, in addition to the hydrophobic cysteine-rich 
secretory (CRISP) domain, some isoforms contain a hydrophilic spacer domain and a putative single transmem-
brane domain (see Supplementary information and Supplementary Fig. 1). This implies that there are both cell 
surface expressed and secreted form of PI16.
PI16 was originally identified as a binding partner to the secreted protein microseminoprotein β (MSMB also 
known as PSP94)35. The function of PI16 in the prostate has not been identified but the serum levels of both PI16 
and MSMB are negatively correlated with prostate cancer progression36, potentially implicating PI16 with inhi-
bition of malignancy by MSMB37. PI16 is also strongly upregulated in human and rodent models of heart failure, 
where it accumulates in the intercellular space and inhibits murine cardiomyocyte growth38. Cardiac specific 
overexpression of full length PI16 reduced the size of cardiac myocytes, while inhibition of PI16 expression lead 
to myocyte hypertrophy, indicating a role for the regulation of cell size through a mechanism yet to be defined38. 
PI16 mRNA and/or protein has also been detected in a wide range of other tissues including the pituitary gland, 
tonsils, heart, small intestine, colon, prostate, testis and ovary35. However, until this current study, PI16 has not 
been shown to have any role in vascular biology. We found that PI16 inhibits migration and the related prolifera-
tion of ECs in vitro, suggesting that it promotes endothelial quiescence. We demonstrated that PI16 is expressed 
in the endothelium of human coronary arteries, consistent with our in vitro findings. PI16 was also present in 
other cells within the intima and media, suggesting other roles that may be the topic of future studies.
Until now, the function and physiological activity of PI16 has remained largely ill-defined. The demonstration 
that PI16 is a potent inhibitor of MMP2, with similar affinity to tissue inhibitors of metalloproteinases (TIMPs)39 
is therefore of particular importance. MMP2 has long been known to participate in the invasion and migration 
of ECs during sprouting angiogenesis20. A similar function of MMP2 in migration and related proliferation of 
vascular smooth muscle cells during repair after vascular injury has also been demonstrated, along with a patho-
logical role in models of aneurysm formation and atherosclerosis40. Inhibition of MMP2 by PI16 could therefore 
have a significant impact on several aspects of vascular pathology beyond endothelial dysfunction, as shown here.
MMP2 also plays a significant role in cancer41,42, MMP2 knockout mice show reduced tumour angiogenesis 
and tumour growth43 and expression of pro-MMP2 is increased in malignant cancers compared to benign can-
cers44,45, with the level of MMP2 expression providing utility as a prognostic marker46,47. In addition to extracellu-
lar actions, MMP2 has been shown to locate to pericellular48,49 and intracellular structures50, with its intracellular 
actions in cardiac myocytes having been shown to contribute to ischemia-reperfusion injury51–53. It is clear that 
MMP2 is an extremely significant protease and the identification of PI16 as a novel inhibitor of MMP2 highlights 
it as a potential regulator of many homeostatic and pathological processes.
Materials and Methods
Cell culture. Human coronary artery endothelial cells (HCAECs; > 6 batches from different donors) were 
bought from Promocell (C-1222) and cultured in MV2 Medium (C-22121-Promocell). HCAECs were seeded 
onto gelatin-coated slides at high density and grown for 48–72 hours before initiation of flow. Cells were placed in 
a parallel plate flow apparatus as previously described15 and exposed to oscillatory flow (0 ± 5 dynes/cm2; OSS), 
normal laminar shear stress (15 dynes/cm2; LSS), or elevated shear stress (75 dynes cm2; ESS) for either 24 or 
72 h. For 24 h shear stress experiments, ERK5 inhibitor BIX 02189 (S1531, SelleckBio 10 μ M), TNFα (5ng/ml), 
or IL-1α (10 ng/ml) were added to media prior to the start of flow as previously described15. For 72 h shear stress 
experiments, cells were allowed to normalise to their respective shear stress environments for 24 h, before thee 
doses of TNFα (5 ng/ml) or control, were injected into the flow apparatus, at 16 h intervals (total treatment time 
of 48 h).
Reverse transcription quantitative PCR (RT-qPCR). RT-qPCR was performed using LightCycler® 480 
SYBR Green I master mix (Roche, UK) on cDNA prepared from HCAECs exposed to OSS, LSS, and ESS for 24 
or 72 h. Standard curves were produced for each primer set and results calculated as copies of cDNA per ng total 
RNA. The primers used to detect all PI16 isoforms were designed based upon common sequences from the full 
length human PI16 gene (accession NM_153370.2; primer sequences in Supplementary Table 1).
Western blotting. Following flow experiments, cells were lysed in SDS lysis buffer [2% SDS; 50 mM Tris pH 
6.8; 10% glycerol]. Cell concentration in the lysate was quantified using PicoGreen (Invitrogen, Renfrew, UK) 
by mixing 100 μ l of 1/1,000 cell lysate with 100 μ l of 1/200 PicoGreen, both diluted in 10 mM Tris, 1 mM EDTA 
(pH 8). Fluorescence was measured with excitation at 485 nm and emission 520 nm and compared to a standard 
curve from a known cell number. 5000 cells were loaded per lane on denaturing SDS–polyacrylamide gels and 
blotted onto PVDF membranes. After blocking, membranes were probed with a primary rabbit anti-PI16 anti-
body (Sigma, UK-HPA043763; 1/3,000) overnight at 4 °C and detected with a HP-linked goat secondary antibody.
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PI16 immunocytochemistry and immunohistochemistry. HCAEC were exposed to shear stress 
before being fixed in cold 4% paraformaldehyde for 10 minutes. Cells were permeabilised with 0.1% triton, 
blocked in 20% goat serum and probed with rabbit anti-PI16 (1:100, Sigma - HPA043763), followed by goat 
anti rabbit Alexa Fluor 488 (1/200, Invitrogen). For immunohistochemistry, paraffin embedded human coro-
nary artery sections were obtained from the Bristol Coronary Biobank (ethical approval 08/H107/48), dewaxed 
and rehydrated. Antigen retrieval was performed with citrate buffer (pH 6.0) incubated in a boiling water-bath 
for 30 minutes. Sections were blocked with 20% goat serum with the addition of pontamine sky blue (0.05%) to 
reduce background autofluorescence. Sections were incubated with rabbit anti-PI16 (1:100, Sigma - HPA043763) 
or rabbit IgG control, followed by goat anti rabbit Alexa Fluor 488 (1/200, Invitrogen). Rhodamine labelled Ulex 
Europaeus Agglutinin I (UEA, 1/200, Vector Laboratories RL-1062) was incubated with the primary antibodies 
to label endothelial cells.
Cloning of PI16 and preparation adenoviral vector. PI16 was amplified with KOD polymerase (Merck 
Millipore) using primers SW653F and SW654R and cloned into a NcoI-deleted version of CpG-mcs (Invivogen) 
using the BglII/NheI restriction sites. The expression cassette from pCpG-mcs containing the mCMV enhancer, 
EF1α promoter, small synthetic intron, PI16 and polyA signal was removed by EcoRI digest and cloned into 
pDC511 (Microbix Biosystems, Canada). PI16 adenoviral vector (AdPI16) was produced using the Microbix 
Biosystems kit according to their protocols. Additionally, the EcoRI digest fragment containing the same expres-
sion cassette and β -galactosidase gene was removed from pCpG-LacZ (Invivogen) cloned into pDC511 and used 
as a vector-matched control (Adβ gal). Viral stocks were amplified, CsCl banded, and titrated by plaque assay. 
AdPI16 gave an unusually low value on plaque assay when assessed at day 11 (normal day of calculation) however 
gave a much higher value when read at day 14 suggesting PI16 overexpression had an inhibitory effect on the 
plaque assay. We used immunocytochemistry to determine the relative pfu needed to achieve 100% transduction 
in HCAECs. Treatment with 25 PFU/cell of PI16 adenovirus lead to the infection of > 95% cells Fig. 3E. Therefore, 
for subsequent experiments, HCAECs were infected with PI16 adenovirus with a multiplicity of infection of 25 
plaque-forming units (PFU) per cell, we used a 4-fold higher pfu/cell for the Adβ gal which gave an equivalent 
infection rate.
Migration and bromo-deoxyuridine (BrdU) incorporation assays. The migration assay was per-
formed using an Ibidi 2D invasion assay Culture-Insert (Ibidi) and proliferation was evaluated by BrdU incorpo-
ration. On day 1, cells were seeded at 1 × 104 cells/partition into culture-inserts. On day 2, cells were transduced 
by either AdPI16 or Adβ -gal for 20 h. On day 3, media were changed. At 4 pm on Day 4, the culture-inserts were 
removed, leaving a 500 μ m cell-free migration gap. Example pictures of the resulting 500 μ m gap were taken using 
a light microscope (10x objective). 16 hours later on the morning of day 5, BrdU (10 μ M, Sigma) was added to 
the media and the cells were left for a further 4 h. Cells were washed (ice-cold PBS) and fixed in 70% ethanol. The 
incorporated BrdU was detected by immunocytochemistry using a mouse anti-BrdU primary antibody (1/500, 
Sigma B8434), biotinylated goat anti-mouse secondary (1/250, Sigma) and Extravidin-HP (1/250, Sigma E2886), 
and visualised with diaminobenzidine staining. The cells were dual labelled with the rabbit anti-PI16 (1:150) 
antibody, signal developed with biotinylated goat anti-rabbit secondary (Sigma 1:250), and ExtrAvidin-Alkaline 
Phosphatase (Sigma, 1:250) and Fast Red TR/Naphthol AS-MX Phosphate (Sigma, UK). Multiple images of the 
wells were taken along the length of the cell-free gap for analysis of migration, as well as in the centre of each 
well for assessment of BrdU staining. For the migration assay, the distance between the two HCAEC populations 
were measured at 10 standardised points on each image. The percentage of cells positive for BrdU staining was 
calculated.
Identification of PI16 binding peptides with phage display. Two populations of HeLa cells were gen-
erated by transduction with either Adβ gal control or AdPI16 and used to isolate binding peptides, as described 
previously28,29. Briefly, 15 μ l (~1 × 1011 pfu) of the phage library (random 12 amino acid library, New England 
Biolabs E8110S) was added to 1 ml 1% bovine serum albumin (BSA) in DMEM + HEPES (Invitrogen, UK), and 
incubated for 1 h at 4 °C on four successive cultures of Adβ gal-transduced HeLa cells (HeLa-β gal). The cleared 
phage library was immediately incubated on HeLa cells infected with PI16-encoding adenovirus (HeLa-PI16), 
at 4 °C for 1 h. Cells were thoroughly washed (× 5) with 1% BSA in PBS (with calcium and magnesium), weakly 
associated phage removed with 0.2 M glycine (pH 2.2), and cells lysed in 30 mM Tris, 1 mM EDTA (pH 8) to 
recover high affinity-bound phage. Subsequent biopanning rounds were performed with ~1 × 1010 phage, and 
included one pre-clearing step on HeLa-β gal cells prior to biopanning on HeLa-PI16 cells. After the comple-
tion of 4 rounds of biopanning, individual phage clones were amplified and screened for enhanced binding to 
PI16-transduced cells. Phage clones that demonstrated selective binding for PI16 were amplified, ssDNA pre-
pared and sequenced. Peptide homology analysis was performed using BLAST.
PI16 activity assay. Static HCAECs were infected with either β -gal- or PI16-expressing adenovirus. 
Following transduction with the virus, cells were washed twice with PBS and endothelial media (MV2 with 
growth factors but no serum) with TNFα (5 ng/ml) was incubated on the cells for 24 hours. Conditioned media 
were collected and concentrated (10x), cells were lysed in SDS lysis buffer and protein concentration assessed 
using the microBCA assay (Pierce). Protease activity of 5 μ l concentrated conditioned media was assessed using 
OmniMMP (Enzo) fluorogenic substrate in MMP buffer [50 mM HEPES, 10 mM CaCl2, 0.15% Brij 35 pH 7.0], 
with 2 mM 4-aminophenylmercuric acetate (APMA). MMP activity was corrected for cell number by dividing the 
fluorescence by the protein concentration of the cell lysate.
Recombinant PI16 was generated by amplifying full length PI16 by PCR using primers SW773F and SW774R 
introducing an in-frame 5’BamHI site and 3′ EcoRI site after the stop codon. PI16 was subcloned into pGEX-6P-1 
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bacterial GST fusion expression plasmid to facilitate the production of recombinant protein. Recombinant PI16 
was expressed in SoluBL21 E. coli (AMS BIOTECHNOLOGY) in media comprising of 50% LB and 50% M9 
media. Overnight culture was diluted 1:100 and grown at 37 degrees with shaking for 4 hours to an approximate 
OD of 0.8, after which it was cooled to 21 °C. PI16 expression was induced for 3 hs by the addition of IPTG at a 
final concentration of 1 mM. The bacterial pellet from 1 litre of culture was resuspended in 25 ml of PBS + pro-
tease inhibitor (Sigma P8340 at 1/100) before being pressure lysed in a Cell Disruptor (Constant Systems) at 
25 kPsi. The lysate was cleared by centrifugation and concentrated using a 15 kDa filter centrifugation unit to a 
volume of 3 ml. The concentrated sample was then diluted back to 15 ml with PBS before being mixed with 500 μ l 
of 4B GST binding sepharose (GE Healthcare) and incubated for 1.5 hs at 4 °C. The beads were then centrifuged 
at 500 g at 4 °C for 5 minutes and the supernatant was discarded. Beads where then washed 3 times with 1.5 ml of 
PBS. PI16 was eluted by thee sequential additions of 500 μ l of 10 mM glutathione (G4251, Sigma). The eluted PI16 
was dialysed (50 kDa MW cut off) into 50 mM HEPES, 10 mM CaCl2 and 100 mM NaCl. Protein concentration 
was measured using the microBCA assay (Pierce) and purity assessed using a SYPRO Ruby-stained polyacryla-
mide gel. In addition, competition for PI16 binding to recombinant MMP2 (Preprotech) was assessed using 
a direct activity assay with fluorogenic OmniMMP substrate (Enzo) using the phage display derived peptide 
TGPRSDGF or the MMP2 derived peptide TGRSDGF at 10 μ M in MMP.
Statistical analysis. Differences between groups were analysed using One-way Analysis of Variance 
(ANOVA), and either a Dunnett’s test to directly compare data with a single control group, or a Bonferroni or a 
Tukey-Kramer post hoc test for multiple comparisons. For two variables, groups were analysed using a two-way 
ANOVA and a Tukey-Kramer post hoc test. The type of analysis used for each experiment is indicated in the figure 
legends. In all instances, p < 0.05 was taken to be statistically significant.
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